Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.50 EUR
Change Today -0.037 / -1.05%
Volume 0.0
As of 2:08 AM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (TG4) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/14/15 - €8.27
52 Week Low
09/9/15 - €2.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THROMBOGENICS NV (TG4)

Related News

No related news articles were found.

thrombogenics nv (TG4) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (TG4) Details

ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes ophthalmic and oncology medicines in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat various disorders, such as cancer, age-related macular degeneration, retinopathy, and inflammation; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc. to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.

120 Employees
Last Reported Date: 04/4/15
Founded in 1991

thrombogenics nv (TG4) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €690.0K
Executive Director
Total Annual Compensation: --
Executive Director and Chairman of Audit Comm...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

thrombogenics nv (TG4) Key Developments

ThromboGenics NV Announces FDA Acceptance of Investigational New Drug Application for Phase II Study with JETREA for the Treatment of Non-Proliferative Diabetic Retinopathy

ThromboGenics NV announced that the FDA has accepted its Investigational New Drug (IND) Application for its CIRCLE study, a Phase II, randomized, double-masked, sham-controlled, multi-center study that will evaluate the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in subjects with non-proliferative diabetic retinopathy. CIRCLE will evaluate JETREA for the treatment of patients with moderately to very severe NPDR and its potential to reduce their risk of progression to Proliferative Diabetic Retinopathy (PDR). The phase II study will be conducted in clinical sites in the United States as well as in several European countries. ThromboGenics and its clinical advisors believe that by using JETREA to generate a PVD, the development of PDR and its sequelae may be prevented. PVD induction eliminates the scaffold for which new blood vessels may bleed into the vitreous.

ThromboGenics NV Presents at KBC Securities 4th Annual Benelux Biotech & Healthcare Seminar, Nov-10-2015

ThromboGenics NV Presents at KBC Securities 4th Annual Benelux Biotech & Healthcare Seminar, Nov-10-2015 . Venue: Convene Grand Central, 101 Park Avenue, at E 41st, New York, NY 10017, United States. Speakers: Patrik De Haes, Chief Executive Officer and Executive Director.

ThromboGenics NV Presents at Benelux Biotech and Healthcare Conference, Nov-09-2015

ThromboGenics NV Presents at Benelux Biotech and Healthcare Conference, Nov-09-2015 . Venue: New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TG4:GR €3.50 EUR -0.037

TG4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TG4.
View Industry Companies

Industry Analysis


Industry Average

Valuation TG4 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.7x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact THROMBOGENICS NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at